These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7520579)

  • 1. PR92 antigen in human prostate fluid: elevated levels in prostate cancer.
    Carlin BI; Marachie J; Venegas MF; Schaeffer AJ; Shaw N; Hass GM; Rademaker AW; Lee C; Grayhack JT
    Prostate; 1994 Sep; 25(3):156-61. PubMed ID: 7520579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody PR92 with restricted specificity for tumor-associated antigen of prostate and breast carcinoma.
    Kim YD; Robinson DY; Tomita JT
    Cancer Res; 1988 Aug; 48(16):4543-8. PubMed ID: 3396007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
    Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
    Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.
    Pretlow TG; Pretlow TP; Yang B; Kaetzel CS; Delmoro CM; Kamis SM; Bodner DR; Kursh E; Resnick MI; Bradley EL
    Int J Cancer; 1991 Nov; 49(5):645-9. PubMed ID: 1718912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
    Oosterom R; Bogdanowicz J; Schröder FH
    Eur Urol; 1989; 16(4):253-7. PubMed ID: 2475344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of the epitope in prostate and breast tumor-associated PR92 antigen.
    Kim YD; Robinson DY; Manderino GL; Tribby II; Tomita JT
    Cancer Res; 1989 May; 49(9):2379-82. PubMed ID: 2468408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic markers and the diagnosis of prostatic cancer.
    Ban Y; Wang MC; Chu TM
    Urol Clin North Am; 1984 May; 11(2):269-76. PubMed ID: 6203206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia.
    Jung K; Lein M; Weiss S; Schnorr D; Henke W; Loening S
    Eur J Cancer; 1996 Apr; 32A(4):627-30. PubMed ID: 8695265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of prostate-specific antigen in the management of localized prostatic cancer.
    Walsh PC; Oesterling JE; Epstein JI; Bruzek DJ; Rock RC; Chan DW
    Prog Clin Biol Res; 1989; 303():27-33. PubMed ID: 2476820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostate-specific antigen in prostatic pathology].
    Teillac P; Peyret C; Leroy M; Najean Y; Le Duc A
    Ann Urol (Paris); 1988; 22(3):193-6. PubMed ID: 2456712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
    Carter HB; Pearson JD; Metter EJ; Brant LJ; Chan DW; Andres R; Fozard JL; Walsh PC
    JAMA; 1992 Apr 22-29; 267(16):2215-20. PubMed ID: 1372942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
    Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
    J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase.
    Ferro MA; Barnes I; Roberts JB; Smith PJ
    Br J Urol; 1987 Jul; 60(1):69-73. PubMed ID: 2441790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of prostate fluid carcinoembryonic antigen in the diagnosis of prostate cancer].
    Hayashi T; Yamauchi A; Hosoda K
    Hinyokika Kiyo; 1995 Jul; 41(7):525-8. PubMed ID: 7545350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia.
    Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
    Am J Med; 1998 Jun; 104(6):517-25. PubMed ID: 9674713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-resolved immunofluorometric assay of human prostate-specific antigen.
    Vihko P; Kurkela R; Ramberg J; Pelkonen I; Vihko R
    Clin Chem; 1990 Jan; 36(1):92-5. PubMed ID: 1688748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
    Shannon BA; Cohen RJ; Garrett KL
    BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate antigen: a new potential marker for prostatic cancer.
    Wang MC; Papsidero LD; Kuriyama M; Valenzuela LA; Murphy GP; Chu TM
    Prostate; 1981; 2(1):89-96. PubMed ID: 6169079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between prostate-specific antigen and prostate volume, evaluated by transrectal ultrasonography: usefulness in diagnosis of prostate cancer.
    Veneziano S; Pavlica P; Querzé R; Nanni G; Lalanne MG; Vecchi F
    Eur Urol; 1990; 18(2):112-6. PubMed ID: 1699766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.